11 results
8-K
VIR
Vir Biotechnology Inc
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
approximately 3,000 men and women ages 18 to 64 without risk factors for serious complications from an influenza infection who did not receive
8-K
EX-99.1
VIR
Vir Biotechnology Inc
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
in the prevention of influenza A illness. The dose-ranging, proof-of-concept trial enrolled approximately 3,000 men and women ages 18 to 64 without risk
8-K
EX-99.1
auj9wdqb2og zl
9 Aug 22
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
yne29mdfemy
5 May 22
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
r368tk4ga5fe7gc
25 Mar 22
Other Events
4:10pm
- Prev
- 1
- Next